159 related articles for article (PubMed ID: 15249447)
1. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension.
Oudiz RJ; Widlitz A; Beckmann XJ; Camanga D; Alfie J; Brundage BH; Barst RJ
Chest; 2004 Jul; 126(1):90-4. PubMed ID: 15249447
[TBL] [Abstract][Full Text] [Related]
2. [Micrococcus blood stream infection in patients receiving epoprostenol].
Mitsutake K; Nogami T
Kansenshogaku Zasshi; 2005 Oct; 79(10):829-30. PubMed ID: 16296331
[No Abstract] [Full Text] [Related]
3. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.
Ivy DD; Calderbank M; Wagner BD; Dolan S; Nyquist AC; Wade M; Nickels WM; Doran AK
Infect Control Hosp Epidemiol; 2009 Sep; 30(9):823-9. PubMed ID: 19637961
[TBL] [Abstract][Full Text] [Related]
4. Intravenous catheter infections in pulmonary arterial hypertension.
Gaine S; Gomberg-Maitland M
Int J Clin Pract Suppl; 2008 Jul; (160):3-4. PubMed ID: 18638169
[No Abstract] [Full Text] [Related]
5. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension.
Akagi S; Matsubara H; Ogawa A; Kawai Y; Hisamatsu K; Miyaji K; Munemasa M; Fujimoto Y; Kusano KF; Ohe T
Circ J; 2007 Apr; 71(4):559-64. PubMed ID: 17384460
[TBL] [Abstract][Full Text] [Related]
6. Bloodstream infections due to Micrococcus spp and intravenous epoprostenol.
Valdivia-Arenas MA
Infect Control Hosp Epidemiol; 2009 Dec; 30(12):1237. PubMed ID: 19888847
[No Abstract] [Full Text] [Related]
7. Micrococcus infection in patients receiving epoprostenol by continuous infusion.
Yap RL; Mermel LA
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):704-5. PubMed ID: 14576986
[No Abstract] [Full Text] [Related]
8. Low incidence of catheter-related complications in patients with advanced pulmonary arterial hypertension undergoing continuous epoprostenol infusion.
Nagai T; Kohsaka S; Anzai T; Yoshikawa T; Fukuda K; Sato T
Chest; 2012 Jan; 141(1):272-273. PubMed ID: 22215838
[No Abstract] [Full Text] [Related]
9. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
10. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628
[TBL] [Abstract][Full Text] [Related]
11. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.
López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Barrios E; Vicente-Hernández M; Aguado JM; Escribano P
Arch Bronconeumol; 2012 Dec; 48(12):443-7. PubMed ID: 22858303
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of bloodstream infection associated with parenteral nutrition.
Opilla M
Am J Infect Control; 2008 Dec; 36(10):S173.e5-8. PubMed ID: 19084152
[TBL] [Abstract][Full Text] [Related]
13. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
Chin KM; Channick RN; Kim NH; Rubin LJ
Chest; 2007 Sep; 132(3):786-92. PubMed ID: 17646224
[TBL] [Abstract][Full Text] [Related]
14. [Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin].
Boucly A; O'Connell C; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
Presse Med; 2016 Jan; 45(1):20-8. PubMed ID: 26547673
[TBL] [Abstract][Full Text] [Related]
15. Bloodstream infections in patients given treatment with intravenous prostanoids.
Kallen AJ; Lederman E; Balaji A; Trevino I; Petersen EE; Shoulson R; Saiman L; Horn EM; Gomberg-Maitland M; Barst RJ; Srinivasan A
Infect Control Hosp Epidemiol; 2008 Apr; 29(4):342-9. PubMed ID: 18462147
[TBL] [Abstract][Full Text] [Related]
16. Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan.
Zaccardelli D; Phares K; Jeffs R; Doran A; Wade M
Int J Clin Pract; 2010 Jun; 64(7):885-91. PubMed ID: 20584221
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of Micrococcus luteus isolates from blood cultures of patients with pulmonary hypertension receiving epoprostenol continuous infusion.
Hirata Y; Sata M; Makiuchi Y; Morikane K; Wada A; Okabe N; Tomoike H
J Infect Chemother; 2009 Dec; 15(6):424-5. PubMed ID: 20012737
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
[TBL] [Abstract][Full Text] [Related]
19. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU.
Warren DK; Zack JE; Mayfield JL; Chen A; Prentice D; Fraser VJ; Kollef MH
Chest; 2004 Nov; 126(5):1612-8. PubMed ID: 15539735
[TBL] [Abstract][Full Text] [Related]
20. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.
Kitterman N; Poms A; Miller DP; Lombardi S; Farber HW; Barst RJ
Mayo Clin Proc; 2012 Sep; 87(9):825-34. PubMed ID: 22883740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
